Pfizer Inc. (PFE) Stock Rating Upgraded by Vetr Inc.
Pfizer Inc. (NYSE:PFE) was upgraded by stock analysts at Vetr from a “buy” rating to a “strong-buy” rating in a report released on Monday. The brokerage presently has a $37.42 target price on the biopharmaceutical company’s stock. Vetr‘s price target indicates a potential upside of 15.14% from the stock’s previous close.
PFE has been the subject of several other research reports. Sanford C. Bernstein reiterated an “outperform” rating on shares of Pfizer in a research note on Monday, September 26th. Piper Jaffray Cos. reiterated an “overweight” rating and set a $54.00 target price on shares of Pfizer in a research note on Monday, June 27th. BMO Capital Markets reiterated a “buy” rating and set a $40.00 target price on shares of Pfizer in a research note on Thursday, July 21st. JPMorgan Chase & Co. set a $40.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Monday, July 25th. Finally, Barclays PLC reiterated an “equal weight” rating and set a $34.00 target price on shares of Pfizer in a research note on Tuesday, August 2nd. Eleven investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus price target of $38.63.
Shares of Pfizer (NYSE:PFE) traded down 0.49% during trading on Monday, hitting $32.50. 16,923,468 shares of the stock were exchanged. The stock has a 50-day moving average of $33.95 and a 200 day moving average of $34.35. The stock has a market cap of $197.13 billion, a P/E ratio of 28.81 and a beta of 0.86. Pfizer has a 12-month low of $28.25 and a 12-month high of $37.39.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/pfizer-inc-pfe-stock-rating-upgraded-by-vetr-inc.html
Pfizer (NYSE:PFE) last released its earnings results on Tuesday, August 2nd. The biopharmaceutical company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.62 by $0.02. Pfizer had a net margin of 14.88% and a return on equity of 23.37%. The firm earned $13.10 billion during the quarter, compared to analyst estimates of $13.01 billion. During the same quarter in the previous year, the firm earned $0.56 earnings per share. The firm’s revenue for the quarter was up 10.9% compared to the same quarter last year. Equities analysts predict that Pfizer will post $2.46 earnings per share for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 1st. Stockholders of record on Friday, November 11th will be issued a $0.30 dividend. The ex-dividend date of this dividend is Tuesday, November 8th. This represents a $1.20 dividend on an annualized basis and a dividend yield of 3.69%. Pfizer’s dividend payout ratio is 95.24%.
Several large investors have recently made changes to their positions in PFE. Lowe FS boosted its stake in shares of Pfizer by 54.9% in the third quarter. Lowe FS now owns 734 shares of the biopharmaceutical company’s stock valued at $23,000 after buying an additional 260 shares during the last quarter. Taylor Wealth Management Partners boosted its stake in shares of Pfizer by 4.3% in the fourth quarter. Taylor Wealth Management Partners now owns 2,555 shares of the biopharmaceutical company’s stock valued at $82,000 after buying an additional 105 shares during the last quarter. Nelson Roberts Investment Advisors LLC boosted its stake in shares of Pfizer by 6.7% in the second quarter. Nelson Roberts Investment Advisors LLC now owns 2,999 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 189 shares during the last quarter. Stelac Advisory Services LLC purchased a new stake in shares of Pfizer during the second quarter valued at approximately $110,000. Finally, Tuttle Tactical Management LLC purchased a new stake in shares of Pfizer during the second quarter valued at approximately $117,000. 69.66% of the stock is owned by institutional investors and hedge funds.
Pfizer Company Profile
Pfizer Inc is a research-based global biopharmaceutical company. The Company is engaged in discovering, developing and manufacturing of healthcare products. Its portfolio includes medicines, vaccines and medical devices, as well as consumer healthcare products. Its products include Prevnar/Prevenar 13, Lyrica, Enbrel, Lipitor, Viagra, Sutent, BeneFIX, Genotropin, ReFacto, Xyntha and Enbrel.
To view Vetr’s full report, visit Vetr’s official website.
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.